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In the  Human  Genome  Project,  the  most  common  type  of  these  variations  is  single  nucleotide  poly-
morphisms  (SNPs).  A large  number  of  different  SNP  typing  technologies  have  been developed  in  recent
years.  Enhancement  and  innovation  for  genotyping  technologies  are  currently  in  progress.  We described
a  rapid  and  effective  method  based  on  real time  ﬂuorescence  quenching  for SNP  detection.  The  new
method,  Quenching-PCR,  offering  a  single  base  extension  method  fully integrated  with  PCR which  used
a probe  with  quencher  to eliminate  ﬂuorophor  of  the  terminal  base  according  to dideoxy  sequencing
method.  In this  platform,  dideoxy  sequencing  reaction  and  obtaining  values  of  real-time  ﬂuorescence
occur  simultaneously.  The  assay  was  validated  by 106 DNA templates  comparing  with  Sanger’s  sequenc-ensitivity
CR
ing  and TaqMan  assay.  Compared  with  the  results  of DNA  sequencing,  the  results  of Quenching-PCR
showed  a high  concordance  rate  of 93.40%,  while  the results  of  TaqMan  platform  showed  a concordance
rate  of  92.45%,  indicating  that  Quenching  PCR  and  TaqMan  assay  were  similar  in accuracy.  Therefore,
Quenching  PCR  will be  easily  applicable  and  greatly  accelerate  the  role  of  SNP  detection  in physiological
processes  of  human  health.
ublis©  2014  The  Authors.  P
. Introduction
In the Human Genome Project, a large number of variations
mong the population have been found (Collins et al., 2003;
achidanandam et al., 2001). The most common type of these vari-
tions is single nucleotide polymorphisms (SNPs). SNPs are sites in
he genome, which have at least two different bases at the same
ocation. These polymorphisms occur in every few hundred bases
n average across the human genome (Gray et al., 2000). Anal-
sis of DNA sequences presents variability between individuals,
nd most of variations in the human genome are attributable to
NPs (Nadeau, 2002). SNPs are inheritable variations that occur
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at least 1% of the population with an average frequency of about
1 in 1000 bp in the human genome (Wang et al., 1998). Current
SNP databases show that there are over 5 million SNPs have been
identiﬁed in the human genome. SNPs detection plays a vital role
in identiﬁcation of disease-causing genes, administration of suit-
able drugs and so on (Schafer and Hawkins, 1998). Among the over
500 genetic diseases, most are associated with genetic variations,
including cancers (Hamano et al., 2010; Huang et al., 2012; Jang
et al., 2013; Jou et al., 2009; Kammerer et al., 2005; Mates et al.,
2012; Yuan et al., 2012), diabetes (Altshuler et al., 2000; Lim et al.,
2012; Unoki et al., 2008; Zhang et al., 2012), Parkinson’s disease
(Noureddine et al., 2005; Simon-Sanchez et al., 2008), autoimmune
disease (Ueda et al., 2003), Alzheimer’s disease (Emahazion et al.,
2001; Martin et al., 2000a,b) and so on.
We reasoned that techniques used in clinical diagnosis should
be suitable for detecting SNPs, considering time cost, sensitivity and
accuracy. Quenching PCR is used as a closed-tube method for geno-
typing that just requires the real-time quantitative PCR equipment.
The ﬁrst step, prior ampliﬁcation. A normal PCR could be performed
on normal PCR equipment. In this step saturating conditions were
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
Sequences of primers and probes.
Name Sequence
ACTN3-F 5′ACACTGCTGCCCTTTCTGTT3′
ACTN3-R 5′CCCCACATCTGAAGATGGAC3′
ACTN3-Probe Q 5′GGCAACACTGCCCGAGGC(BHQ1)TGAC3′
′ ′
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Fig. 1. Overview of Quenching-PCR platform.
A  schematic representation of complex (not to scale). On the Quenching-PCR plat-
form, a probe with quencher is used to eliminate ﬂuorophor of the terminal base
or  a terminal base with quencher is used to eliminate ﬂuorophor of probe accord-
ing to dideoxy sequencing method. Quenching PCR mainly contained four steps. In
this essay, two  main steps: prior amplication and real-time ﬂuorescence quenching
reaction were elaborated.
(A) Process of prior ampliﬁcation.
In prior ampliﬁcation of Quenching PCR, the reaction system included DNA
(15–20 ng), rTaq PCR Polymerase, 10 mM dNTP, 25 mM Mg2+, forward and reverse
primers. The progress of prior ampliﬁcation was  composed of an initial polymerase
activation at 95 ◦C for 5 min, followed by 15 cycles at 95 ◦C for 30 s, with annealing
at  65 ◦C (−1 ◦C/cycle) for 30 s and 72 ◦C for 45 s, and 20 cycles at 95 ◦C for 30 s, with
annealing at 50 ◦C for 30 s and 72 ◦C for 45 s. The prior ampliﬁcation was performed
on  PTC200 machine (BioRad).
(B) Main components of real-time ﬂuorescence quenching reaction.
After puriﬁcation for prior ampliﬁcation product, Exonuclease I and alkaline phos-
phatase took away remained dNTPs and primers in the process of prior ampliﬁcation.
Then, Fluorescein-12-ddCTP, R6G-ddUTP, Probe Q and prior ampliﬁcation product
were prepared for the next step of real-time ﬂuorescence quenching reaction. Probe
Q  was  produced by ligating a quencher (Black Hole Quencher-1, BHQ1) to a base,
which was near the end of each probe (3′ end), about 4–12 bases. Fluorescein-12-
ddCTP and R6G-ddUTP were purchased in Perkin-Elmer (USA).
(C) Real-time ﬂuorescence quenching reaction for different alleles.
On the Quenching-PCR platform, a probe with quencher is used to eliminate ﬂu-
orophor of the terminal base based on dideoxy sequencing method. Probe Q was
produced by ligating a quencher (Black Hole Quencher-1, BHQ1) to a base, which
was near the end of each probe (3′ end), about 4–12 bases. When dideoxy sequenc-
ing reaction worked, either of ddNTP with a ﬂuorophor was combined to the 3′ end
of  probe, and then the ﬂuorescence from ddNTP was quenched by the quencher
BHQ1 included in the probe. When the Probe Q met  the allele G, Fluorescein-12-
ddCTP was combined, and then the quencher BHQ1 eliminated the ﬂuorescence
from Fluorescein-12, which demonstrated that ﬂuorescence on Passage FAM fell
down. On the other hand, when the Probe Q met  the allele A, R6G-ddUTP was  com-
bined, then the quencher BHQ1 eliminated the ﬂuorescence from R6G-ddUTP, which
demonstrated that ﬂuorescence on Passage JOE fell down.COMT-F 5 GGGCCTACTGTGGCTACTCA3
COMT-R 5′CCCTTTTTCCAGGTCTGACA3′
COMT-Probe Q 5′TCAGGCATGCACACCTTGT(BHQ1)CCTTCA3′
ully created for next steps. The second step, puriﬁcation for prior
mpliﬁcation product, pure DNA without dNTPs and primers which
ould affect genotype in the next step was supplied. The third
tep, real-time ﬂuorescence quenching reaction, the most impor-
ant step in the whole experiment. In this step, we would get the
ata of real-time ﬂuorescence value. The last step is the data anal-
sis, the change of real-time ﬂuorescence value between the ﬁrst
ycle and the last cycle for Passage FAM and Passage JOE was  sep-
rately calculated. Eventually we would get genotypes for loci of
ach template.
Hereby, we  reported the successful adaptation of Quenching PCR
o SNP detection. Our templates are human oral cavity epithelium
ucosal cells, but the approach would be easily applicable to any
NA samples. Our experimental results conﬁrmed that Quenching
CR will be easily applicable and will have great effect on clinical
iagnosis.
. Material and methods
.1. Template preparation
In the Quenching PCR, TaqMan assay and DNA sequencing
xperiments, genotypes of 106 templates were assayed. The codes
f the SNP locus tested were ACTN3-rs1815739 and COMT-rs4680.
e  compared results of Quenching PCR to those results obtained
rom the DNA sequencing system and TaqMan assay with the
ame templates. Samples were from human oral cavity epithelium
ucosal cells left on the WhatmanTM paper (G.E., China), which
ere provided by volunteers. DNA templates were extracted with
he EZgeneTM Blood gDNA Miniprep Kit (Biomiga GD2311, China),
ollowing the protocol of the handbook.
.2. Quenching PCR: prior ampliﬁcation condition
Primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
Table 1). The reaction system included 1 L DNA (15–20 ng), 0.2 L
f 5 U/L  rTaq PCR Polymerase, 0.3 L of 10 mM dNTP, 1.2 L of
5 mM Mg2+, 1 L of both primers and 8.8 L ddH2O. The progress
f prior ampliﬁcation was composed of an initial polymerase acti-
ation at 95 ◦C for 5 min, followed by 15 cycles at 95 ◦C for 30 s,
ith annealing at 65 ◦C (−1 ◦C/cycle) for 30 s and 72 ◦C for 45 s, and
0 cycles at 95 ◦C for 30 s, with annealing at 50 ◦C for 30 s and 72 ◦C
or 45 s. The prior ampliﬁcation was performed on PTC200 machine
BioRad) (Fig. 1(A)).
.3. Quenching PCR: puriﬁcation for prior ampliﬁcation product
The reaction system included 3 L prior ampliﬁcation prod-
ct, 1 L Exonuclease I (1 U/L) and 1 L Alkaline Phosphatase
1 U/L). Exonuclease I could catalyze the removal of nucleotides
rom single-stranded DNA in the 3′ to 5′ direction, while
lkaline phosphatase was a valuable reagent for removal of
erminal monoesteriﬁed phosphate from both ribo- and deoxyribo-
ligonucleotide. Therefore, Exonuclease I and alkaline phosphatase
ook away remained dNTPs and primers in the process of prior
mpliﬁcation. The puriﬁcation lasted for 30 min  at 37 ◦C and for
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5 min  at 80 ◦C, which was also performed on PTC200 machine
BioRad).
.4. Quenching PCR: real-time ﬂuorescence quenching reaction
The realtime ﬂuorescence quenching reaction was  performed
n 7900 Realtime PCR System (Applied Biosystems, USA) with
 5 L reaction volume. For each reaction, 2.4 L puriﬁed prior
mplication product was mixed up with 0.1 L Therminator DNA
olymerase, 0.5 L 10× Therminator DNA Polymerase Buffer (NEW
NGLAND BIOLABS), 0.5 L Fluorescein-12-ddCTP, 0.5 L R6G-
dUTP (Perkin-Elmer) and 1 L Probe Q (20 M)  (synthesized by
erfectus Biotechnology Co., Ltd., China) (Table 1). All the reactions
onsisted of one cycle at 95 ◦C for 5 min, 40 cycles at 95 ◦C for 20 s,
1 ◦C for 30 s and 72 ◦C for 30 s, and detection passages were chosen
s FAM and JOE.
Probe Q was made by ligating a quencher (Black Hole Quencher-
, BHQ1) to a base, which was near the end of each probe (3′ end),
bout 4–12 bases. When dideoxy sequencing reaction worked,
ither of ddNTP with a ﬂuorophor was combined to the 3′ end of
robe, and then the ﬂuorescence from ddNTP was quenched by the
uencher BHQ1 which was included in the probe (Fig. 1(B)).
For example, COMT (rs4680) had two alleles, base G and base
, so we used related ddNTP, ddCTP and ddUTP. When the Probe
 met  the allele G, Fluorescein-12-ddCTP was combined, and the
uencher BHQ1 eliminated the ﬂuorescence from Fluorescein-12,
hich demonstrated that ﬂuorescence on Passage FAM fell down,
ndicating the locus of such a sample had an allele G. On the other
and, when the Probe Q met  the allele A, R6G-ddUTP was  com-
ined, and the quencher BHQ1 eliminated the ﬂuorescence from
6G-ddUTP, which demonstrated that ﬂuorescence on Passage JOE
ell down, conﬁrming the locus of such a sample had an allele A.
hen the SNP locus was heterozygous, the Probe Q would elimi-
ate the ﬂuorescence on both passages, which meant the locus of
he sample had both allele G and allele A (Fig. 1(C)).
.5. Quenching PCR: data analysis
After 40 cycles of real-time ﬂuorescence quenching reaction, we
ould get the data of real-time ﬂuorescence value for every cycle
n Passage FAM and Passage JOE. Then the variation of real-time
uorescence value between the ﬁrst cycle and the last cycle for
assage FAM and Passage JOE was separately calculated. We would
etermine genotype for each sample in accordance with the data
nalyzed. Data analysis was conducted under three circumstances.
nder the circumstances that proportion of relative changes on Pas-
age FAM occupies above 67.7% of total changes on both passages,
e determinate that the genotype is homozygote (For example
f COMT-rs4680. When proportion of relative changes on Pas-
age FAM occupies 85% of total changes on both passages, we
dded Fluorescein-12-ddCTP and R6G-ddUTP into the mix, then
e could determine that the genotype is G/G). Under the circum-
tances that proportion of relative changes on Passage JOE occupies
bove 67.7% of total changes on both passages, we determinate that
he genotype is homozygote (For example of COMT-rs4680, when
roportion of relative change on the Passage JOE occupies 85% of
otal changes on both passages, we added Fluorescein-12-ddCTP
nd R6G-ddUTP into the mix, then we could determine that the
enotype is A/A). Under the circumstances that proportion of rel-
tive changes on Passage FAM or Passage JOE occupies between
3.3% and 67.7% of total changes on both passages, we  determinate
hat the genotype is heterozygote (For example of COMT-rs4680,
hen proportion of relative change on Passage FAM occupies 55%
nd proportion of relative change on Passage JOE occupies 45% of
otal changes on both passages, we added Fluorescein-12-ddCTPlogy 186 (2014) 156–161
and R6G-ddUTP into the mix, then we  could determine that the
genotype is G/A).
2.6. Quenching-PCR: linearity and reproducibility
Prior ampliﬁcation and puriﬁcation was  performed as described
in “Quenching PCR: prior ampliﬁcation condition” and “Quenching
PCR: puriﬁcation for prior ampliﬁcation product” above. A prior
ampliﬁcation product was respectively diluted at primary con-
centration of 50%, 25%, 12.5%, 6.25%, 3.12%, 1.56%, 0.78%. Total
nine groups include primary product and control group. Then, the
reaction condition was followed as “Quenching PCR: realtime ﬂu-
orescence quenching reaction”.
2.7. Quenching-PCR: sensitivity
The prior ampliﬁcation system included 1 L DNA (0.3125,
0.625, 1.25, 2.5, 5, 10, 20 ng, respectively), 0.2 L of 5 U/L rTaq
PCR Polymerase, 0.3 L of 10 mM dNTP, 1.2 L of 25 mM Mg2+,
1 L of both primers and 8.8 L ddH2O. The reaction condition was
followed as “Quenching PCR: prior ampliﬁcation condition”. After
prior ampliﬁcation, the other steps were the same as “Quenching
PCR: puriﬁcation for prior ampliﬁcation product” and “Quenching
PCR: realtime ﬂuorescence quenching reaction”.
2.8. Sanger’s sequencing
With the 106 templates used in Quenching PCR, we planned to
compare the results between Quenching PCR and Sanger’s sequenc-
ing. In Sanger’s sequencing, PCR was  performed as described in
“Quenching PCR: prior ampliﬁcation condition”. After ampliﬁca-
tion, PCR products were sent to Shanghai Huaguan Biochip Co. Ltd.
to get DNA sequences, according to Sanger’s sequencing.
2.9. TaqMan assay
With the 106 templates used in Quenching PCR, we planned to
compare the results between Quenching PCR and the TaqMan assay.
In TaqMan assay, two SNPs were selected from the SNP informa-
tion (http://www.hapmap.org) supplied by NCBI (National Centre
for Biotechnology Information). Locus-speciﬁc PCR primers and
allele-speciﬁc TaqMan® probes (COMT, rs4680, C 25746809 50;
ACTN3, rs1815739, C 590093 1) were designed and supplied by
Applied Biosystems (USA). All genotyping assays had a FAMTM or
VIC® reporter dye at the 5′ end of each TaqMan® MGB  probe and
a nonﬂuorescent quencher at the 3′ end of each probe. PCR was
performed on 7900 Realtime PCR System (Applied Biosystems, Fos-
ter City, CA, USA) in a 5 L reaction volume. For each PCR, 2.25 L
genome DNA (15–20 ng) was  mixed with 2.5 L 2× TaqMan univer-
sal PCR master mix  and 0.25 L 20× Taqman SNP genotyping assay
mix. All the reactions consisted of one cycle at 95 ◦C for 10 min, 40
cycles at 95 ◦C for 15 s, 60 ◦C for 1 min.
3. Results
3.1. Quenching-PCR platform overview
The Quenching-PCR platform was based on classic sequencing
established by Sanger. This assay used a probe with quencher to
eliminate ﬂuorophor of the terminal base according to dideoxy
sequencing method. In the assay, Fluorescein-12-ddCTP, R6G-
ddUTP, Probe Q, Therminator DNA Polymerase and DNA were
necessary. Prior ampliﬁcation was fundamental, which created
enough templates for next steps. Then, the step of puriﬁcation sup-
plied pure DNA without dNTPs and primers which could affect
Y. Xu et al. / Journal of Biotechnology 186 (2014) 156–161 159
Table  2
Genotypes of 106 samples.
Gene Variation Genotype
CC(GG) TC(GA) TT(AA)
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Fig. 2. Realtime ﬂuorescence.
(A) Realtime ﬂuorescence for genotype of G/G.
Template, whose genotype of COMT-rs4680 was  G/G determined by Sanger’s
sequencing, was  used in Quenching PCR. This ﬁgure for real-time ﬂuorescence indi-
cated that ﬂuorescence on Passage FAM fell down during the whole process, while
ﬂuorescence on Passage JOE almost hadn’t changed. Due to the Fluorescein-12-
ddCTP and R6G-ddUTP added in the reaction, the changes on Passage FAM reﬂect
the Fluorescein-12-ddCTP consumption, which conﬁrms the genotype was G/G.
(B)  Realtime ﬂuorescence for genotype of G/A.
Template, whose genotype of COMT-rs4680 was G/A determined by Sanger’s
sequencing, was  used in Quenching PCR. This ﬁgure for real-time ﬂuorescence indi-
cated that ﬂuorescence on Passage FAM and JOE fell down during the whole process.
Due to Fluorescein-12-ddCTP and R6G-ddUTP added in the reaction, the changes on
Passage FAM and JOE stood that both Fluorescein-12-ddCTP and R6G-ddUTP had
been consumed, which meant the genotype was  G/A.
(C) Realtime ﬂuorescence for genotype of A/A.
Template, whose genotype of COMT-rs4680 was  A/A determined by Sanger’sACTN3 rs1815739 20 26 15
COMT rs4680 11 34 0
enotype in the next step. After puriﬁcation, real-time ﬂuores-
ence quenching reaction was performed, in which step, we  would
btain the data of real-time ﬂuorescence value. At last, data analysis
as needed. The change of real-time ﬂuorescence value between
he ﬁrst cycle and the last cycle for Passage FAM and Passage JOE
as separately calculated. Then we would get genotypes for loci of
ach template. Real-time ﬂuorescence for each genotype has been
howed in Fig. 2.
.2. Performance of Quenching-PCR
Each reaction contained 15–20 ng DNA, two  ddNTPs, and
herminator DNA Polymerase plus Probe Q. In addition, three
egative-controls were included in every reaction. We  also exam-
ned the linearity, dynamic range and reproducibility on a sample
hose genotype had been known. Data showed that amount of
.25 ng DNA template was limited for detection. The assay was
lso highly linear with linear regression correlation coefﬁcients of
ounts versus concentration at ≥0.98 (p < 0.0001) based on statisti-
al analysis of two-tailed Pearson’s Correlation and paired student’s
-test (Fig. 3). Genotype of the 106 templates had been provided in
able 2 and Fig. 4. Comparing with the results of Sanger’s sequenc-
ng, the results of Quenching PCR showed a high concordance rate
93.40%). However, Quenching-PCR has an advantage in time cost,
ctually about half of the time cost by DNA sequencing.
Comparing with the results of DNA sequencing, the results of
aqMan platform showed a concordance rate (92.45%). We  also
ound that there was no obvious difference between Quenching-
CR and TaqMan Platform according to Fisher’s Test (p = 0.498,
 > 0.1).
. Discussion
In the past years, a large number of new SNP typing technolo-
ies have been developed, which are based on various methods of
llelic discrimination and detection platforms. Enhancement and
nnovation for genotyping technologies are in progress (Sobrino
t al., 2005; Steﬂ et al., 2013).
On the Quenching PCR platform, when dideoxy sequencing
eaction and value obtainment of real-time ﬂuorescence occur
imultaneously. Allele-speciﬁc detection during real-time ﬂuo-
escence reaction can be obtained by ddNTPs with different
uorescences. A single probe labeled with a quencher (BHQ1) is
sed to identify the detail location of SNP. When the dideoxy
equencing reaction works, the quencher (BHQ1) combines ﬂuores-
ence nearby. Then, the changes for ﬂuorescence would be detected
t the same time. Unique probe with quencher is required for each
arget, and synthesis and puriﬁcation for labeled probe are triv-
al. No further step for detection would be required. This is more
ompelling when comparing to other popular techniques for SNP
etection such as Matrix assisted laser desorption/ionization time-
f-ﬂight mass spectrometry (MALDI-TOF MS)  and SNP microarray
Fei and Smith, 2000; Shumaker et al., 1996). In terms of MALDI-
OF MS,  after extensive reaction, extensive products are detected
y mass spectrometry and the difference between mass of exten-
ive products and primer identiﬁes that incorporate nucleotides
ould be obtained (Haff and Smirnov, 1997; Taketomi et al., 1997).
sequencing, was  used in Quenching PCR. This ﬁgure for real-time ﬂuorescence
turned out that ﬂuorescence on Passage JOE fell down within the whole process,
while ﬂuorescence on Passage FAM almost hadn’t changed. On account of the input
of  Fluorescein-12-ddCTP and R6G-ddUTP in the reaction, the changes on Passage JOE
manifested the R6G-ddUTP consumption. The genotype A/A was then conﬁrmed.
160 Y. Xu et al. / Journal of Biotechno
Fig. 3. Linearity and reproducibility on Quenching-PCR.
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.25%, 3.12%, 1.56%, 0.78%. Total nine groups contain primary product and control
roup. The R2 value of a linear for this data is 0.9838, p < 0.0001.
etection is also required in SNP microarray. After arrayed primer
xtension (APEX) by a DNA polymerase with labeled ddNTPs, the
icroarray needs to be scanned for measurement (Pastinen et al.,
997; Patil et al., 2001; Tan et al., 2013; Xu et al., 2013).
Clinical studies are greatly limited by technical aspects of SNP
enotyping, sensitivity, speciﬁcal accuracy and cost-effectiveness
Kim and Misra, 2007). Sensitivity is always an obstacle in clini-
al diagnosis and limited by nonspeciﬁc ampliﬁcation at low initial
emplate copy number (Kanemitsu et al., 2013; Ririe et al., 1997;
oong and Iacopetta, 1997). The detection limit of Quenching PCR
s 1.25 ng of DNA template, similar to other popular primer exten-
ion assays or techniques for SNP detection such as SNaPshot (ABI)
nd MALDI-TOF MS  (SEQUENOM), or allele-speciﬁc hybridization
ig. 4. Relative ﬂuorescence changes on FAM and JOE Passage for 106 samples.
he sum of relative ﬂuorescence changes on FAM and JOE passage was  100%. Gen-
rally, one locus of SNP had two alleles (A/B), so there were totally three genotypes
A/A, A/B, B/B). In this case, we divided the quadrant into three parts on average. X
xis represented relative ﬂuorescence changes on FAM Passage, while Y axis repre-
ented relative ﬂuorescence changes on JOE Passage. In the right-down part, relative
uorescence changes on FAM Passage were above 67.7% (relative changes on JOE
assage were below 33.3%), we  could determine that the genotype was C/C (G/G) (if
luorescein-12-ddCTP and R6G-ddUTP were used). In the middle part, relative ﬂuo-
escence changes on FAM Passage were between 33.3% and 67.7% (relative changes
n  JOE Passage were between 33.3% and 67.7%), and we could determine that the
enotype was T/C (G/A) (if Fluorescein-12-ddCTP and R6G-ddUTP were used). In the
eft-up part, relative ﬂuorescence changes on JOE Passage were above 67.7% (relative
hanges on FAM Passage were below 33.3%) we could determine that the genotype
as  T/T (A/A) (if Fluorescein-12-ddCTP and R6G-ddUTP were used).logy 186 (2014) 156–161
assays such as TaqMan (ABI) (Brion et al., 2005; Fei et al., 1998;
Fei and Smith, 2000; Inagaki et al., 2004). However, Quenching PCR
is used as a closed-tube method for genotyping that requires the
real-time quantitative PCR equipment. As we know, these meth-
ods we mentioned above will rely on expensive equipments such
as Genetic Analyzer (ABI, 3130/3130XL) and Massarray Analyzer
(SEQUENOM) (Bradic et al., 2011; Cantor, 2012; Huang and Pan,
2007; Yuan et al., 2013). Based on qualiﬁed DNA, the results of
Quenching PCR showed a high concordance rate (93.40%) com-
paring with the results of Sanger’s sequencing, which had no
obvious difference with TaqMan Platform. However, design of
TaqMan probe is a puzzle, and frequently researchers had been
trying for a few times until ﬁnal success. Sanger’s sequencing is
dependent upon the controlled interruption of the enzymatic repli-
cation of an ssDNA template by DNA polymerase incorporation of
dideoxynucleotide terminators (Sanger et al., 1977). Although DNA
sequencing is capable of measuring unknown locus, its shortcom-
ing is time-consuming, which is not suitable for clinical detection
within a short period. MALDI-TOF MS,  is also not an optimal tech-
nique for detecting SNP. The fact is that the smallest mass difference
of 9 Da can be detected, but it is difﬁcult to distinguish between
A/T, A/A and T/T genotypes (Fei et al., 1998), which would affect
the accuracy SNP detection on clinical diagnosis. PCR is compati-
ble with many dsDNA-speciﬁc dyes, such as ethidium bromide and
ethidium homodimer, which have been used for monitoring the
quality of PCR product for decades (Tombler and Deutsch, 1993).
Although ethidium bromide is available and inexpensive, its toxic-
ity can not be avoided. Indeed, Quenching PCR is a process in a gel
free environment without any dsDNA-speciﬁc dye and gel. Sanger’s
sequencing and SNaPshot (ABI) are inevitable to use gels. On  the
other hand, in Quenching PCR, one reaction well could detect an
SNP for two alleles, just as Taqman Assay. If the SNP has more than
two alleles, another reaction well could be added to monitor all the
variations. Furthermore, the method could not only detect SNP, but
also could detect particular insertion-deletions (InDel). Condition
for using Quenching PCR to detect InDel is that the ﬁrst base of the
InDel sequence is different from the ﬁrst base following the InDel
sequence.
5. Conclusions
Quenching-based real-time PCR is a single base extension
(SBE) method fully integrated with PCR. The combination of
dideoxy sequencing reaction with ﬂuorescence quenching pro-
vides a potential approach for simultaneous reaction and detection.
Quenching PCR will have great effect on SNP detection of clinical
diagnosis.
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